Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging

Condition(s) studied

Investigational drug(s) / intervention(s)

⁶⁸Ga-PSMA PET/CT: PSMA PET imaging performed for clinical evaluation in prostate cancer patients, used as a comparator for physiologic salivary gland PSMA uptake.

⁶⁸Ga-FAPI PET/CT: FAPI PET imaging to assess inflammatory activity (FAPI) in patients with primary Sjögren's syndrome.

Study summary

Primary Sjögren's syndrome (pSS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration, progressive destruction of salivary gland acini, and varying degrees of functional impairment and fibrosis. Conventional imaging provides limited ability to simultaneously evaluate glandular function and inflammatory activity, leading to challenges in disease staging and treatment decision-making. This study explores a conceptual dual-tracer imaging framework using PSMA PET and FAPI PET to delineate complementary biological processes in pSS.

Eligibility

Primary outcome measure(s)

• Difference in Salivary Gland PSMA Uptake Across Groups — Baseline
  Quantitative comparison of PSMA PET uptake parameters (SUVmax, SUVmean) of the parotid glands among three groups: pSS patients, individuals with normal salivary glands, and prostate cancer patients.

Trial sites (1)

More Peking Union Medical College Hospital trials in China

Other trials for the same condition